BioCatalyst

Adagrasib oral dose of 400 mg twice daily tablets, Pembrolizumab, Chemotherapy: Pemetrexed, Cisplatin/Carboplatin — catalyst calendar

1 verified catalyst event(s) referencing Adagrasib oral dose of 400 mg twice daily tablets, Pembrolizumab, Chemotherapy: Pemetrexed, Cisplatin/Carboplatin, each linked to its official source. Verified as of 2026-08-06.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-09-30
in 2mo
ESTIMATED
 READOUT
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G
Phase 2 · Advanced NSCLC, Metastatic Lung Cancer
 Mirati Therapeutics Inc. Adagrasib oral dose of 400 mg twice dail ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.